Skip to main content
KLRA logo

Kailera Therapeutics, Inc.

KLRANASDAQHealthcareBiotechnology

$11.25Today:- (-)

As of Oct 16, 2026 close

Market cap
$1.20B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$9.76$28.23
Volume (live)
-
Avg. volume (3M)
1.34M

Kailera Therapeutics (KLRA) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Kailera Therapeutics had return on equity of -36.9%, debt-to-equity of 0.02 (up from 0.00), a current ratio of 12.02 (down from 25.70) and return on assets of -22.7%. A current ratio of 12.02 means current assets exceed current liabilities.

Kailera Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024
Period endingDec 2025Dec 2024
Valuation Ratios
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)-36.90%-
Return on Assets (ROA)-22.73%-
Return on Capital Employed (ROCE)-24.50%-14.30%
Leverage & Solvency Ratios
Debt/Equity0.020.00
Liquidity Ratios
Current Ratio12.0225.70
Quick Ratio11.8325.35
Efficiency Ratios
Yield & Distribution Ratios

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Kailera Therapeutics Financial Ratios

What is Kailera Therapeutics's return on equity?

Kailera Therapeutics's return on equity (ROE) was -36.9% for fiscal 2025 (period ended Dec 31, 2025).

What is Kailera Therapeutics's debt-to-equity ratio?

Kailera Therapeutics's debt-to-equity ratio was 0.02 for fiscal 2025 (period ended Dec 31, 2025). It was 0.00 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition